Last checked at 13 Jun 2019 14:16
Shield Therapeutics plc
("Shield" or the "Group")
Result of 2019 Annual General Meeting
London, UK, 13th June 2019: Shield Therapeutics plc (LSE:STX), a commercial stage, specialty pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the results of the proxy vote for each of the resolutions set out in the Notice of AGM.
The following table shows the votes cast on each resolution:
VOTESFOR | % | VOTESAGAINST | % | VOTESTOTAL | % of ISC VOTED | VOTESWITHHELD | |
1 | 91,099,593 | 99.16 | 769,230 | 0.84 | 91,868,823 | 78.46% | 0 |
2 | 86,706,679 | 94.40 | 5,144,503 | 5.60 | 91,851,182 | 78.45% | 17,641 |
3 | 91,079,163 | 99.14 | 789,611 | 0.86 | 91,868,774 | 78.46% | 49 |
4 | 86,767,461 | 94.45 | 5,101,313 | 5.55 | 91,868,774 | 78.46% | 49 |
5 | 91,868,823 | 100.00 | 0 | 0.00 | 91,868,823 | 78.46% | 0 |
6 | 85,998,231 | 93.61 | 5,870,543 | 6.39 | 91,868,774 | 78.46% | 49 |
7 | 91,065,998 | 99.14 | 790,943 | 0.86 | 91,856,941 | 78.45% | 11,882 |
8 | 91,835,228 | 99.97 | 29,777 | 0.03 | 91,865,005 | 78.46% | 3,818 |
9 | 74,183,338 | 80.76 | 17,677,421 | 19.24 | 91,860,759 | 78.45% | 8,064 |
10 | 74,179,520 | 80.76 | 17,677,421 | 19.24 | 91,856,941 | 78.45% | 11,882 |
11 | 17,401,749 | 18.94 | 74,455,192 | 81.06 | 91,856,941 | 78.45% | 11,882 |
12 | 91,856,941 | 100.00 | 0 | 0.00 | 91,856,941 | 78.45% | 11,882 |
The Board reports that resolutions 1 to 9 passed as ordinary resolutions and resolutions 10 and 12 were passed as special resolutions. Special resolution 11 was not passed, however resolutions 9 and 10 were obtained which authorise the Company to allot equity share capital including the right to issue up to 5% of issued share capital disapplying pre-emption rights.
Notes
1. Percentage of shares voted: 78.46% (Number of shares in issue 117,088,657).
2. Details of the votes received on the resolutions are available on the Company's website: https://www.shieldtherapeutics.com/investors/corporate-documents/.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71
- Ends -
For further information please contact:
Shield Therapeutics plc | www.shieldtherapeutics.com |
Carl Sterritt, Chief Executive Officer | +44 (0)20 7186 8500 |
Tim Watts, Chief Financial Officer | |
Nominated Advisor and Broker | |
Peel Hunt LLP | |
James Steel/Dr Christopher Golden | +44 (0)20 7418 8900
|
Joint Broker | |
finnCap Ltd | +44 (0)20 7220 0500 |
Geoff Nash /Matt Radley/ Alice Lane |
|
Walbrook PR | +44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus / Helen Cresswell | +44 (0)7980 541 893 / +44 (0)7841 917 679 |
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com.